Semaglutide

Efinopegdutide achieved higher rates of MASH resolution and meaningful fibrosis improvement versus placebo at 52 weeks, with a safety profile broadly similar to semaglutide.

Post hoc ESSENCE subgroup (n=106) showed improvements in ALT, AST, FAST, ELF and PRO‑C3 at week 72 versus placebo; findings presented at AASLD 2026.

Real‑world cohorts showed Wegovy 2.4 mg was associated with larger reductions in body weight, AST/ALT, and HbA1c versus resmetirom or no semaglutide in adults with MASH.

Q3 revenue rose 39% to $24.4B; 2026 revenue outlook raised to $91–$92B. Q3 included ~$900M of benefits and $4.2B IPR&D charges; multiple FDA approvals and positive late‑stage readouts reported.

Post hoc REDEFINE 1 analyses found once‑weekly cagrilintide/semaglutide produced large weight and waist‑circumference reductions across menopausal stages; main adverse events were gastrointestinal. FDA decision expected Q4 2026.

Oral orforglipron showed 5–11% weight loss at 72 weeks and 1.2–1.9 percentage‑point HbA1c reductions; CHMP opinion now goes to the European Commission for an EU licence.

MRI‑PDFF subanalysis (n=55) found mean liver fat fell from 8.8% to 3.1% at week 72; 88.5% with baseline liver fat >5% reached <5%.

Ro telehealth real-world data: mean 4.1% weight loss at three months; 40.7% reached ≥5% loss; obesity (BMI≥30) prevalence fell 21.6 percentage points; N=194.

fMRI shows reduced ‘food noise’ and cravings; trials report major weight loss, reductions in abdominal/liver/pancreas fat and preliminary bone‑marker reassurance.

Real-world claims analysis found escalating from semaglutide 1 mg to 2 mg tied to a 6% lower risk of major adverse cardiovascular events than switching to tirzepatide.